Mental illness PSAs: broad industry support sought for schizophrenia education program by NARSAD.
MENTAL ILLNESS PSAs: BROAD INDUSTRY SUPPORT SOUGHT for a public service advertising campaign on schizophrenia that will be similar to the PSA recently launched by the National Alliance for Research on Schizophrenia and Depression with the Ad Council to educate the public on the role of new medicines and therapies in treating depression and other mental illnesses. The organization would prefer support from a broad consortium of companies rather than individual pharmaceutical firms, citing worries voiced by the Ad Council that corporate support could cloud the message by casting doubt on the credibility of the source.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth